(VELA) Study of BLU-222 in Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|HR+ Breast Cancer|CCNE1 Amplification|HER2-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer|Gastric Cancer|Esophageal Adenocarcinoma|Carcinosarcoma
Interventions: DRUG: BLU-222|DRUG: Carboplatin|DRUG: Ribociclib|DRUG: Fulvestrant
Sponsor: Blueprint Medicines Corporation